News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News 📰

Aerosol Delivery Device Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: January 2024 || SKU: MD7803
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Get Free Sample

See how US Tariffs impact Aerosol Delivery Device Market

Don’t get cau

Global Aerosol Delivery Device Market is segmented By Product (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers) By Applications (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Non-Respiratory Diseases) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

Global aerosol delivery device market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Aerosol is a suspension system of solid or liquid particles in a gas, typically air. It allows for medication to be delivered directly to the bloodstream through the lungs, without the complications of an IV, such as pain and injection site infection. This technique is primarily used for dosing medication for lung conditions, including asthma, but it may be beneficial for other therapies as well.

Market Scope

Metrics

Details

CAGR

YY%

Market Size Available for Years

2022-2031

Estimation Forecast Period

2024-2031

Revenue Units

Value (US$ Mn) 

Segments Covered

Product, Application, Distribution Channel

Regions Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Largest Region

North America

Fastest Growing Region

Asia-Pacific

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

 

For more details on this reportRequest for Sample

 

Market Dynamics: Drivers & Restraints

Growing Prevalence of Respiratory Diseases

The growing prevalence of respiratory diseases is expected to boost the global market growth during the forecast period. For instance, according to the World Health Organization (WHO) 2021 factsheet, COPD was among the third-leading reason of death globally, inducing 3.23 million casualties in 2020. More than 80% of these casualties happened in low and middle-income countries (LMIC). 

Also, according to the Asthma and Allergy Foundation of America in March 2021, approximately 1 in 13 Americans had asthma, which was approximately 25 million individuals. Asthma is among the biggest contributors to this formation, involving children, adults, and geriatric individuals. The same reference remarked that almost 5 million American children had asthma.

Furthermore, the technological advancements, rise in research activities, increaseing investments and growing awareness are among the other additional factors boosting the global market growth during the forecast period.

Product Recalls

The increasing incidences of product recalls from market are expected to hamper the global market growth during the forecast period. for instance, Cipla Limited's wholly-owned associate, Cipla USA Inc., willingly recalled six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) manufactured in November 2021 to the consumer level with the knowledge of the U.S. Food and Drug Administration. Furthermore, stringent regulatory bodies, and high development costs are other additional factors hampering the global market growth during the forecast period.

Segment Analysis

The global aerosol delivery device market is segmented based on product, application, distribution channel and region.

Metered Dose Inhalers are Expected to Dominate Market

Owing to the increasing authorizations from the regulatory bodies for metered dose inhalers, the segment is expected to dominate the global market during the forecast period. For instance, in October 2021, BreatheSuite obtained 510(k) authorization from the FDA for its Metered-Dose Inhaler V1 device, which turns existing inhalers into smart inhalers for individuals with asthma and COPD. Moreover, in July 2023, Lupin's subsidiary unit Hormosan Pharma GmbH introduced a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increasing approvals in North America the region is expected to dominate the global market during the forecast period. For instance, in July 2023, Viatris Inc., a multinational healthcare corporation, and Kindeva Drug Delivery introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the foremost generic version of AstraZeneca's Symbicort with an Abbreviated New Drug Application (ANDA) authorized by the U.S. Food and Drug Administration (FDA). Moreover, in February 2020, The US Food and Drug Administration (FDA) authorized the foremost generic of ProAir HFA (albuterol sulfate) inhalation aerosol to treat or prevent bronchospasm in individuals of four years of age and older with reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients four years of age and older.

COVID-19 Impact Analysis

As SARS-CoV-2 directly targets the lungs and initiates lung damage, treating COVID-19 with inhalants presents multiple benefits over the enteral/parenteral administration. Inhaled drug delivery delivers higher drug concentrations, particularly in the pulmonary system. This allows the lessening of systemic side effects and delivers a quick clinical reaction, therefore, the pandemic has led to an increase in the demand for and investments in aerosol delivery devices, positively impacting the global market during the pandemic.

Key Developments

  • In June 2022, United Therapeutics Corporation obtained FDA authorization for its Tyvaso DPI, an inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension linked with interstitial lung diseases. 
  • In January 2023, AstraZeneca obtained authorization from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra strives to decrease the threat of asthma exacerbations in people aged 18 years and older.

Competitive Landscape

The major global players in the market include 3M Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Pfizer Inc, Merck & Co., Inc., Genentech USA, Inc. and MannKind Corporation among others.

Why Purchase the Report?

  • To visualize the global aerosol delivery device market segmentation based on product, application, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of aerosol delivery device market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global aerosol delivery device market report would provide approximately 62 tables, 58 figures and 184 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Buy this report
Single User
$4350$3480
Multiple User
$4850$3880
Enterprise User
$7850$6280
Proceed to Buy
  Get Free Sample
  Customize Sample
  Demo Full Report
Chat on WhatsApp
Related Reports
medical-devices iconmedical-devices

Dry Powder Inhalers Market Size, Share, Industry, Forecast and outlook (2025-2033)

Published: 2025 January 06

Starting from

$4350

medical-devices iconmedical-devices

Smart Inhalers Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2025 May 12

Starting from

$4350

medical-devices iconmedical-devices

Inhalation Therapy Nebulizer Market Size, Share, Growth Trends and Forecast 2024-2031

Published: 2025 May 15

Starting from

$4350

medical-devices iconmedical-devices

Respiratory Inhalers Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2023 December 05

Starting from

$4350

WhatsApp